ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1065

Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis

Adarsh Ravishankar1, Daisy Yan2, Christina Bax3, Josef Symon Concha2, Bridget Shields4, Lisa Pappas-Taffer4, Rui Feng5, Joyce Okawa4 and Victoria Werth2, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 5University of Pennsylvania, Philadelphia

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Cutaneous, dermatomyositis, diet, Myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been reported to incite an immune response or induce dermatomyositis (DM), cutaneous lupus erythematosus (CLE) or autoimmune blistering diseases (AIBD). Given these potential effects, there is a need to characterize CAM usage in patients.

Methods: We performed a retrospective chart review of prospectively-collected data at the University of Pennsylvania to characterize CAM usage among patients with DM, CLE, AIBD (including pemphigus vulgaris and bullous pemphigoid), and controls without autoimmune disease. Information gathered included demographic information, disease history, and CAM usage and duration (Spirulina, Chlorella, Alfalfa, Green Algae, Echinacea, or other). CAM use was elicited in a stepwise manner, starting with asking patients open-ended questions about CAM use, followed by handing a flyer that lists herbal supplements to aid with recall. Statistical analysis was performed using logistic regression to calculate odds ratios (OR), accounting for race and sex as covariates, at a significance level of 0.05.

Results: 372 patients were enrolled, including 158 DM (42.5%), 122 CLE (32.8%), 31 AIBD (8.3%), and 61 controls (16.4%). All cohorts were predominantly female and Caucasian. DM had the greatest proportion of Caucasians (81.6%), followed by controls (78.7%), AIBD (61.3%), and CLE (52.5%). CAM use was reported in 12.1% of all patients (19.6% of DM, 5.7% of CLE, 6.5% of AIBD, and 8.2% of controls). Spirulina was the most frequently-used herbal supplement for DM (14.6%), CLE (4.1%), and controls (5.7%), while blue-green algae was the most frequently-used CAM for AIBD (3.2%). Herbal use in DM was greater compared to controls (OR = 2.37, p = 0.0919), and compared to other autoimmune cohorts (OR = 3.47, p = 0.0032).  Spirulina use was greater among DM patients compared to both controls (OR = 2.34, p = 0.1345) and to other autoimmune cohorts (OR = 4.92, p = 0.0027). Herbal and spirulina use were not significantly associated with non-DM autoimmune diseases compared to controls.

Conclusion: Our study demonstrates that CAM use, in particular spirulina, is greater among patients with DM. This association is statistically significant for DM compared to CLE or AIBD. This study demonstrates that the use of CAM is of concern among the patients with a history of DM. Patients with DM should be educated regarding the risk of onset or flare from using immunostimulatory CAM such as Spirulina.

Patient Demographics (%)

Herbal supplement use for each cohort (%)

Logistic regression comparison of herbal and spirulina use between cohorts


Disclosure: A. Ravishankar, None; D. Yan, None; C. Bax, None; J. Concha, None; B. Shields, None; L. Pappas-Taffer, None; R. Feng, None; J. Okawa, None; V. Werth, Biogen, 2, 5.

To cite this abstract in AMA style:

Ravishankar A, Yan D, Bax C, Concha J, Shields B, Pappas-Taffer L, Feng R, Okawa J, Werth V. Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/immunostimulatory-herbal-supplement-use-is-more-common-among-patients-with-dermatomyositis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunostimulatory-herbal-supplement-use-is-more-common-among-patients-with-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology